Speaker Bios - Massachusetts Biotechnology Council

The Strategic Outlook to 2015 

April 14, 2009 

Seaport World Trade Center 

Program Guide

Look for our 2009 event schedule at 

massbio.org 

May 18 – 21 

Massachusetts Pavilion at the BIO 2009 

International Convention, 

Georgia World Congress Center 

June 3 

Massachusetts Life Sciences Innovation Day, 

Sheraton Boston Hotel 

June 4 

Member Networking Open House, 

The Liberty Hotel 

September 11 

Annual MBEF Golf Classic, 

Stow Acres Country Club 

October 6 

MassBIO Investors Forum, 

Sheraton Boston Hotel

Welcome 

Welcome to the 2009 Massachusetts Biotechnology Council Annual Meeting! 

This has certainly been a busy year for all of us. We have retooled and repurposed our programs and services 

to better address the needs of our members. We moved from celebrating the landmark $1 billion Life Science 

Initiative and focused on its implementation through the regulation process. We worked with the Life Sciences 

Center to convene hundreds of company executives, academic and health care institution leaders, and other 

key stakeholders to discuss their thoughts and vision for the new law and how they see it positioning them for 

success. 

We have also been confronted with significant economic challenges—challenges that the MBC is being proactive 

in helping our members meet and conquer. Not only will today’s working sessions help us collectively craft new 

and efficient solutions to the challenges of increasing collaborations and building our workforce, these themes 

will be carried through all of MBC’s 2009 programming. 

We are planning to build on the 2008 MassBio Investors Forum to assemble and match up companies with investors 

and disease foundations and ignite a dialogue around creative ways to receive funding in these difficult economic 

times. We have launched our new Pharma Days to provide an opportunity for pharmaceutical company teams 

present to small biotech companies and create partnerships. Additionally, we have initiated and implemented a 

comprehensive communications plan to promote the economic value of the industry in Massachusetts and the 

impact on patients worldwide, including our radio and TV campaign, MBC News quarterly newsletter and a new 

MassBio.org. 

Today at our 2009 Annual Meeting, you will see first-hand how we intend to move not only our organization 

forward, but also a roadmap that will empower us to maintain our position as the leader in life sciences around 

the world. The 2015 Strategic Report will lay the foundation for a collaborative effort to solidify Massachusetts’ 

standing as the premier biotechnology cluster. 

We at the MBC are committed to ensuring we create and sustain an environment in which each of our members 

can achieve its full potential. We are equally committed to industry’s role in driving the economy and most 

importantly solving unmet medical needs for patients around the world. 

Thank you for joining us as we celebrate another successful year at the Massachusetts Biotechnology Council 

and prepare for the future. Please enjoy our robust program of speakers, panel discussions and most impotantly 

the camaraderie of networking with your fellow industry leaders and visionaries. Speak up, ask questions and 

share ideas. The future of our industry is in our collective hands. 

Sincerely, 

Robert K. Coughlin 

President & CEO 

Mark Leuchtenberger 

Chairman, MBC Board of Directors 

1

Agenda 

10:00 a.m. – 11:00 a.m. Open House with Fisher Scientific 

11:00 a.m. – 11:15 a.m. Welcome and Opening Remarks (Amphitheater) 

Robert K. Coughlin, President and CEO, MBC 

Mark Leuchtenberger, Chairman, MBC Board of Directors 

11:15 a.m. – 12:30 p.m. Overview of the MBC 2015 Strategy Report (Amphitheater) 

Moderator: 


2 

The 2015 Report outlines the challenges and opportunities we face as we work 

to keep the Massachusetts biotech cluster at the forefront of the industry. 

The co-authors of this report are Deloitte Consulting and L.E.K. Consulting. 

Speakers: 

Sanjay Behl, Principal, Deloitte Consulting LLP 

Barri S. Falk, Specialist Leader, Life Sciences and Healthcare, 

Deloitte Consulting LLP 

Matthew Hudes, National Managing Principal for 

Biotechnology, Deloitte Consulting LLP 

Andrew Vaz, National Leader, Life Sciences, 

Deloitte Consulting LLP 

12:45 p.m. – 2:15 p.m. Keynote Luncheon (Harborview Ballroom) 

Presentation of 2008 MBC Innovative Leadership Award to 

Fereydoun Firouz, CEO, EMD Serono, Inc. 

2:15 p.m. – 2:45 p.m. Break 

2:45 p.m. – 3:45 p.m. Concurrent Forum Sessions 

I. Efforts to Attract, Develop and Retain Talent in Massachusetts 

(Waterfront Room) 

What are we doing to keep local biotech talent in state and incentivize others to relocate to Massachusetts 

Talent is the main driver of Massachusetts’s success as a cluster but the availability of qualified scientists, research 

associates, and technicians is becoming an increasing challenge. Demand for highly qualified biotech talent is growing, 

both in traditional R&D and in expanding downstream business sectors, such as clinical trials, bio-manufacturing, and 

commercialization. The quality of the skilled workforce in Massachusetts, typically those with advanced graduate degrees 

and doctorates, is among the finest in the United States; however, our high cost of living makes the Commonwealth a less 

attractive location for retaining talent and attracting associate-degreed biotech workers. Although the state has many 

excellent higher education and training programs in life sciences, these programs are not always well coordinated and 

could be made more responsive to the changing needs of the industry. What activities offer the best rate of return to 

support development, retention, and attraction of talent at all levels to fill the growing needs of the Massachusetts cluster 

Moderator: 

Eric Marcheski, Marchon Partners 


Dr. Carole A. Cowan, President, Middlesex Community College 

Jim Ellard, CEO, New England Biolabs 

Christopher Perley, Vice President and General Manager, 

Bristol-Myers Squibb

Agenda 

2:45 p.m. – 3:45 p.m. Concurrent Forum Sessions 

II: Science, Industry, Collaboration, and Innovation in Massachusetts 

(Amphitheater) 

“There is a tenuous link between academia and industry - We need to figure out how to organize us more efficiently to 

accelerate discovery and translational capabilities.” 

What are we doing to better align the academic community and industry to improve research and funding collaborations 

The Massachusetts Cluster is a leader, but our value proposition could decline if we lose our position as the frontrunner 

in innovation. How can we best facilitate interactions between academia and industry to reduce clinical trial barriers 

and improve the technology transfer process How can we foster more meaningful collaborations among academia, VCs 

and industry to reduce reliance on “chance” partnerships What are the potential areas for proactive investments or 

collaborations in innovative and breakthrough technologies 

Moderator: 

Ronald A. DePinho, M.D., Director, 

Belfer Institute for Applied Cancer Science, 

Professor of Medicine and Genetics, 

Dana-Farber Cancer Institute, 

Harvard Medical School 

3:45 p.m. – 4:00 p.m. Break 


Barry Greene, President and COO, 

Alnylam Pharmaceuticals, Inc. 

Edwin Kania, Managing Partner and Chairman, 

Flagship Ventures 

Lita Nelsen, Director of the MIT Technology 

Licensing Office 

Gerald E. Quirk, Vice President and General 

Counsel, Infinity Pharmaceuticals, Inc. 

4:00 p.m.– 5:00 p.m. Success in a Recession The Economic Outlook (Amphitheater) 

“Access to capital and decreasing NIH funding are the two biggest financial challenges the Massachusetts Cluster will face 

in maintaining its cutting edge science, innovation and competitive positioning.” 

The biotech industry is facing unprecedented challenges as a result of the current economic, policy, and regulatory 

environment. Biotech companies in Massachusetts need to anticipate these challenges and develop strategies to enhance 

their chances for survival and create opportunities that enable them to succeed. 

Moderator: 

Robert Buderi, Founder, CEO, 

Editor in Chief , Xconomy 

5:00 p.m. – 5:30 p.m. Closing Remarks (Amphitheater) 


Dr. Ernie Berndt, Louis B. Seley Professor 

of Applied Economics, MIT Sloan School 

Jonathan J. Fleming, Managing General Partner, 

Oxford Bioscience Partners 

Frank Hatheway, Chief Economist, 

the NASDAQ OMX Group Inc. 

The Hon. Deval L. Patrick, Governor, The Commonwealth of Massachusetts 

5:30 p.m. – 7:00 p.m. Closing Cocktail Reception (Amphitheater Lobby) 

3

Speaker Bios 

Sanjay Behl, Principal, Deloitte Consulting LLP 

Mr. Behl is a principal in the Strategy and Operations practice in Atlanta, GA where he serves pharmaceutical 

clients. His expertise includes working with core industry issues related to pharmaceutical sales and marketing 

(commercial), revenue enhancement, corporate and business unit strategy. 

Mr. Behl has 15 years of pharmaceutical R&D and marketing experience with global pharmaceutical clients. 

Sample engagements include developing a corporate strategy, growth strategy, therapy area strategy for the 

largest therapy area of a global pharmaceutical company, developing a global franchise plan for a key Therapy 

Area of a mid-size global pharmaceutical company, integrating sales organizations after the merger of two major 

multi-national pharmaceutical companies, and identifying potential target companies in UK’s primary healthcare 

market for an investment fund. 

He has an MBA from INSEAD and a Ph.D. in materials science and engineering. He has lived and worked in the 

United States and Europe and served a number of pharmaceutical companies in both the United States and 

Europe. 

Ernst R. Berndt, Louis E. Seley Professor in Applied Economics, MIT Sloan School, 

and Co-Director, MIT-Harvard Biomedical Enterprise Program 

Professor Berndt’s research focuses on the changing dynamics of health care industries. Among his recent 

research are articles in Nature Reviews: Drug Discovery, “Stratified Medicine: Strategic and Economic 

Implications of Combining Drugs and Clinical Biomarkers” (joint with Mark Trusheim and Frank Douglas), 

and “Trends in the Globalization of Clinical Trials” (joint with Fabio Thiers and Anthony Sinskey). He has just 

finished a book manuscript comparing vaccines, biologics and small molecule pharmaceuticals through the entire 

product life cycle from discovery, intellectual property protection, development and post-launch surveillance 

(U.S. Markets for Vaccines: Characteristics, Case Studies, and Controversies”, joint with Rena Denoncourt and 

Anjli Warner), forthcoming later this spring from the AEI Press. Together with Murray Aitken and David Cutler he 

recently published a Health Affairs article examining near term prospects for the US biopharmaceutical industry, 

“Prescription Drug Spending Trends in the US: Looking Beyond the Turning Point”. 

Robert Buderi, Founder, CEO, Editor in Chief, Xconomy 

Before launching Xconomy, Mr. Buderi was a research fellow in MIT’s Center for International Studies. 

He previously served as Editor in Chief of MIT’s Technology Review, leading the magazine to numerous editorial and 

design awards and overseeing its expansion into three foreign markets, its introduction of electronic newsletters, 

and its organization of highly successful conferences. Earlier, as BusinessWeek’s technology editor, he shared in 

the 1992 National Magazine Award for “The Quality Imperative,” a special issue of the magazine . Mr. Buderi is also 

the author of three books about technology and innovation. Guanxi (2006) looks at Microsoft’s Beijing research 

lab as a metaphor for global competitiveness. Engines of Tomorrow (2000) describes the evolution of corporate 

research. The Invention That Changed the World (1996) examines the work of a secret lab at MIT during World War II. 

Mr. Buderi served on the Council on Competitiveness-sponsored National Innovation Initiative and as an advisor to 

the Draper Prize Nominating Committee. He has been a regular guest of CNBC’s Strategy Session and has spoken 

about innovation to many organizations, including the Business Council, Amazon, eBay, Google, IBM, and Microsoft. 

4



Mr. Coughlin is a former state representative and businessman. In his leadership role within Governor Deval 

Patrick’s administration, he worked to retain and recruit life science organizations and other key businesses for 

the state. He is very familiar with all areas of the Massachusetts life sciences super cluster and is a passionate 

advocate for the research and biotechnology community. 

A graduate of the Massachusetts Maritime Academy and lieutenant in the United States Naval Reserve, 

Mr. Coughlin has also been active in the community, serving on the boards of the Academy and Beth Israel 

Deaconess Hospital, as honorary chairman of the Great Strides Cystic Fibrosis Walk, and as a member of the 

National Volunteer Leadership Board, among other organizations. 

Dr. Carole A. Cowan, President, Middlesex Community College 

President, Carole A. Cowan is the president of Middlesex Community College, the largest and most comprehensive 

community college in the Commonwealth of Massachusetts. Dr. Cowan joined the college in 1976 as a faculty 

member in the business division. She has served as Dean of the Business Division, Dean of Administration and 

Finance, and, in September of 1990, was named president of the college. 

Dr. Cowan received a bachelor’s and master’s degree from Salem State College, a Certificate of Advanced Graduate Study 

from Boston State College, and a doctorate in Higher Education Administration from the University of Massachusetts 

at Amherst. She also received an honorary degree, Doctor of Humane Letters, from the Suffolk University College of 

Liberal Arts and Sciences and School of Management, in recognition of her distinguished career in public higher education. 

In October 2000, she was selected as one of the first recipients of a Women’s Business Hall of Fame Award for her 

extraordinary vision and deep commitment to the advancement of the mission of community colleges. 

Under her leadership, the college weathered the most severe budget cuts in the history of the state, during which 

time she successfully secured permanent campuses in Bedford and Lowell. President Cowan also led the development 

of the commonwealth’s first privately financed capital pool to construct MCC’s Health, Science, and Technology 

Center. Support from the Middlesex Community College Foundation enabled her to oversee the restoration of the 

historic Nesmith House in Lowell which now serves as MCC’s Center for Economic Development and International 

Programs. During the last five years, Dr. Cowan has established international training programs and provided technical 

assistance and exchange opportunities for students, faculty, and clients in Eastern Europe and Asia. Under her 

leadership, Middlesex Community College has developed partnerships in 27 countries. 

Locally, partnership initiatives with area businesses and public school systems have put Middlesex in the forefront 

of economic and workforce development as well as education reform. Middlesex established one of the state’s first 

Charter Schools, and sponsors an alternative Middle School in Lowell. It also is the only community college in 

Massachusetts to operate a One-Stop-Career Center, a Massachusetts Department of Labor initiative consolidating all 

state employment and training programs. 

Dr. Cowan has served on the American Council on Education’s (ACE) International Commission and the American 

Association of Community Colleges (AACC) International Commission. She also served as co-chairperson for the 

Massachusetts Campus Compact, a state-wide consortium of private and public colleges and universities with service 

learning programs, and she sits on the Presidents’ Advisory Council of the Association of Community College Trustees. 

5


Ronald A. DePinho, M.D., Director, Belfer Institute for Applied Cancer Science, 

Professor of Medicine and Genetics, Dana-Farber Cancer Institute, Harvard Medical School 

Dr. DePinho is a co-founder of AVEO, holds the coveted American Cancer Society Research Professorship, and is Professor 

of Medicine and Genetics at Harvard Medical School. He is the director of the Belfer Institute for Applied Cancer Science 

at the Dana-Farber Cancer Institute. His research program has made major discoveries of fundamental importance to 

cancer medicine, aging, and degenerative disorders. He has been a leader in the field of molecular genetics and in the 

development of mouse models of human cancer. His independent scientific career began at the Albert Einstein College of 

Medicine, where he was the Senior Scholar in Cancer Research and launched the first mouse genome engineering program 

to model and study the genetic basis of cancer. He is now a member of the Department of Medical Oncology at the 

Dana-Farber Cancer Institute and Department of Medicine and Genetics at Harvard Medical School. Dr. DePinho is a 

former member the Board of Directors of the American Association for Cancer Research, chairs advisory boards for the NCI 

Mouse Models of Human Cancer Consortium and the NIH Human Cancer Genome Altas Project, and serves on numerous 

advisory boards for the public and private sectors. 

Dr. DePinho studied Biology at Fordham University, where he graduated Class Salutatorian and received his M.D. with 

distinction in Microbiology and Immunology from the Albert Einstein College of Medicine. His honors and awards include 

the March of Dimes Basil O’Connor Award, James S. McDonnell Scholar Award, the Cancer Research Institute Scholar 

Award, the Melini Award for Biomedical Excellence, the Irma T. Hirshcl Award, Kirsch Foundation Investigator Award, and 

the Richard and Claire Morse Scholar Award. He is the 2002 recipient of the American Society for Clinical Investigation 

Award, the 2003 AACR Clowes Award, and most recently, received the 2009 Albert Szent Gyorgyi Award for Progress in 

Cancer Research. He is a member of the National Academy of Science Institute of Medicine. 

Jim Ellard, CEO, New England Biolabs 

James Ellard is CEO of New England Biolabs, Inc. (NEB), a world leader in the development and production of reagents that 

enable biotechnology research. After receiving his Bachelor of Science degree in the Life Sciences from Massachusetts 

Institute of Technology, he joined NEB as a bench scientist working on the expression and purification of DNA modifying 

enzymes. He then went on to direct the Marketing Communications department, a position he held for 15 years. In 2005, 

Mr. Ellard was appointed as CEO, bringing to this position more than two decades of experience in marketing, business 

development, brand management, and strategic planning in the Life Science industry. Active in business and community 

affairs, he has served in various positions, including Corporate Trustee of the Trustees of Reservations, the Board of Save 

One Life, the Board of BioHelix Corp. and the Board of Associates for the Whitehead Institute for Biomedical Research. 

Barri S. Falk, Specialist Leader, Life Sciences and Healthcare, Deloitte Consulting LLP 

Ms. Falk is a Specialist Leader in Deloitte’s Life Sciences Consulting Practice. She has more than 20 years of Life Sciences 

and Healthcare management experience and co-leads the Life Sciences Commercial Practice’s point of view on lifecycle 

management and product launch. 

Prior to joining Deloitte, Ms. Falk spent 10 years as the Vice President, Marketing and Vice President, Managed Markets for 

the U.S. subsidiary of a global biotechnology company. Her areas of expertise include strategic planning, brand strategy 

and planning, commercialization, alliance management, marketing, product launch, lifecycle management and managed 

markets pricing, contracting, and reimbursement. She has extensive experience in driving strategic thinking, leading 

teams through complex business situations, and working cross-functionally within a matrixed organization to build 

consensus and achieve actionable results. 

Ms. Falk earned her Master in Health Systems Management with a focus in Strategy and Business Planning. 

6


Fereydoun Firouz, President and CEO, EMD Serono, Inc. 

Mr. Fereydoun Firouz is President and CEO of EMD Serono, Inc. In this capacity, his responsibilities include driving the 

strategic direction of the U.S. organization as well as managing the day-to-day operations of the U.S. affiliate of 

Merck KGaA, Darmstadt, Germany. He is a member of the Executive Management Committee of Merck Serono.* 

Previously, Mr. Firouz was Executive Vice President, Reproductive Health North America, where he was 

responsible for re-engineering the sales and marketing organization for the company’s U.S. Reproductive Health 

business. From 1998 to 2001, Mr. Firouz was Vice President, Latin America for Serono S.A., where he oversaw the 

successful launches of a variety of products. Prior to his tenure in Latin America, Mr. Firouz held positions of 

increasing responsibility in EMD Serono, Inc.’s IBO region as Director and ultimately Vice President, where he was 

instrumental in creating new operating entities in Greece, Turkey, Israel, Central Europe, and the Middle East. 

Mr. Firouz began his career at EMD Serono, Inc., in 1989 as a Government Affairs Associate in the company’s 

Washington, D.C. office. 

Mr. Firouz is an active participant and board member of the Biotechnology Industry Organization (BIO), 

Pharmaceutical Research and Manufacturers of America (PhRMA), and the Massachusetts Biotech Council 

(MBC). Under his leadership, EMD Serono, Inc., has been the recipient of numerous corporate awards, 

including, most recently, the Boston Business Journal’s Corporate Philanthropy Award, given to companies in the 

Boston area with exceptional charitable programs. 

Mr. Firouz received his Bachelor of Science in political science from George Washington University in 

Washington, D.C. He has also participated in a number of executive education programs, including the 

Executive Program on General Management at the F. W. Olin Graduate School of Business at Babson College. 

His leisure interests include skiing, squash, filmmaking, and art. 

*Merck Serono S.A. is an affiliate of Merck KGaA, Darmstadt, Germany. 

The division Merck Serono operates in North America under the name EMD Serono, Inc. 

Jonathan J. Fleming, Managing General Partner, Oxford Bioscience Partners 

Mr. Fleming is the Managing General Partner of Oxford Bioscience Partners (OBP), an international venture 

capital firm specializing in life science technology-based investments, with offices in Boston and Connecticut. 

Mr. Fleming has been in the investment business for more than 20 years, starting and financing growth companies 

in the United States, Europe, and Israel. Prior to joining OBP in 1996, he was a Founding General Partner of 

MVP Ventures in Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, 

Germany. Mr. Fleming has also co-founded Medica Venture Partners, a venture capital investment firm 

specializing in early stage healthcare and biotechnology companies in Israel. 

Mr. Fleming holds a Master’s degree in Public Administration from Princeton University and a Bachelor of Arts 

degree from the University of California, Berkeley. 

Mr. Fleming is on the board of Asterand and is a director of several private companies, including Leerink Swann, 

a Boston-based investment bank specializing in health care companies. Mr. Fleming is a Trustee of the Museum 

of Science in Boston, a Member of the Board of the New England Healthcare Institute, and a Senior Lecturer at 

the MIT Sloan School. 

7


Barry Greene, President and COO, Alnylam Pharmaceuticals, Inc. 

Mr. Greene joined Alnylam Pharmaceuticals, Inc., in September 2003, bringing more than 15 years of experience in health 

care industries and consulting. Prior to joining Alnylam Pharmaceuticals, Inc., he was General Manager of Oncology at 

Millennium Pharmaceuticals, Inc., where he led the company’s global strategy and execution for its oncology business 

including strategic business direction and execution, culminating in the successful approval and launch of VELCADE 

(bortezomib) in mid 2003. Prior to joining Millennium in February 2001, Mr. Greene served as Executive Vice President 

and Chief Business Officer for Mediconsult.com. Prior to Mediconsult.com, Mr. Greene’s past experiences include 

Vice President of Marketing and Customer Services for AstraZeneca, formerly AstraMerck; Vice President Strategic 

Integration with responsibility for the AstraZeneca North American post merger integration; and Partner, Andersen 

Consulting responsible for the pharmaceutical/biotechnology marketing and sales practice. 

Mr. Greene received his Bachelor of Science degree in Industrial Engineering from University of Pittsburgh. 

He also serves as Senior Scholar at Duke University, Fuqua School of Business and is a Board Member of Acorda 

Therapeutics, Inc., Regulus Therapeutics, LLC and the Biomedical Enterprise Program, Harvard MIT Division of Health 

Sciences and Technology - a joint program of Harvard Business School and MIT Sloan School. 

Frank Hatheway, Chief Economist, NASDAQ 

Dr. Hatheway is Chief Economist of the NASDAQ OMX Group Inc., and is responsible for a variety of projects and initiatives 

to support the markets and improve market structure. Since joining NASDAQ OMX, he has carried out a number of 

studies on NASDAQ and other markets, developed NASDAQ’s opening and closing auctions, and advised on major 

corporate initiatives such as the launch of the NASDAQ Options Market and NASDAQ OMX Europe. 

Prior to joining NASDAQ OMX, Dr. Hatheway was a finance professor at Penn State University and a researcher in market 

microstructure. He has authored academic articles in the Journal of Finance, Journal of Financial Intermediation and other 

leading finance journals. Dr. Hatheway has served as an Economic Fellow and Senior Research Scholar with the U.S. 

Securities and Exchange Commission and received his Ph.D. in Economics from Princeton University. 

Matthew Hudes, National Managing Principal for Biotechnology, Deloitte Consulting LLP 

Mr. Hudes is U.S. Managing Principal, Biotechnology, for Deloitte’s Life Sciences and Health Care practice. In this role, 

he develops, provides and leads the practice’s professional services, working with Tax, Audit, Consulting, and Financial 

Advisory Services, for this dynamic industry sector. Previously, he was the Chairman and CEO of Accélère, a software 

company that developed a system to find patients (and investigators) for clinical trials and to improve researchers’ access 

to information typically “trapped” in laboratory and medical systems. 

Mr. Hudes has provided strategic professional services to leading biotechnology and pharmaceutical companies, 

including Amgen, Biogen Idec, Chiron, Genentech, Johnson and Johnson, and Sanofi-Aventis. He speaks frequently about 

topics such as the use of technology for innovating clinical research, manufacturing and quality, regulatory compliance, 

and supply chain. 

Formerly, Mr. Hudes led the global Capgemini Life Sciences Biotechnology and R&D practice. As a former Partner and 

practice leader with Ernst & Young LLP, he acted as a strategic advisor to leading-edge companies in life sciences and high 

technology over a period of 17 years. Mr. Hudes was a founding management team member of three start-up companies, 

one of which had a successful IPO and was subsequently acquired. The other two were successfully acquired by larger 

companies. 

Mr. Hudes has a Bachelor of Arts degree in Psychology from the University of Connecticut, Storrs, CT and an MBA from 

Santa Clara University, Santa Clara, CA with a concentration in Operations and Management Information Systems. 

8


Edwin Kania, Managing Partner and Chairman, Flagship Ventures 

Mr. Kania has 25 years of experience in the venture capital industry. Prior to co-founding Flagship Ventures in 

2000, he spent 14 years as General Partner of OneLiberty Ventures and of its predecessor firm, Morgan, Holland 

Ventures. From 1983 to 1984, he served as an Investment Officer at First Capital Corporation of Boston, the 

venture capital subsidiary of Bank of Boston, and, previously, as Research Associate at Harvard Business School 

and as General Manager at J. Cunningham, Inc. He is a frequent speaker on venture capital and entrepreneurship. 

Mr. Kania earned his undergraduate degree in physics from Dartmouth College and his MBA from Harvard 

Business School. While at Dartmouth and HBS, he was an All-American Track and Field athlete, a national 

and collegiate record holder, and a member of the Pacific Coast Club, a track club based in Long Beach, CA. 

Throughout his professional career, Mr. Kania has operated both as an investor and as an active partner to 

entrepreneurs in company building. His direct investment experience covers over 100 companies. In addition, he 

has been intimately involved in the launch and development of more than a dozen companies as the founding, lead or 

co-lead investor, and on occasion has assumed operating roles in support of management. Several of these companies 

are now publicly traded while others have been acquired by significant publicly-traded companies. The total value 

of the companies in which Mr. Kania has participated as founding or lead investor is currently several billion dollars. 

Mr. Kania has served as a Director of Adolor (Nasdaq: ADLR), Alere Corp., Anesta Corp. (Nasdaq: NSTA, purchased 

by Cephalon, Nasdaq: CEPH), AudioLogic (purchased by Cirrus Logic, Nasdaq: CRUS), ChemGenics 

Pharmaceuticals (purchased by Millennium, Nasdaq: MLNM), Cytyc Corp. (Nasdaq: CYTC), Ontogeny (merged 

into Curis, Nasdaq: CRIS), PerSeptive Biosystems (Nasdaq: PBIO, purchased by Applera, NYSE: ABI), Somatogen 

(Nasdaq: SMTG, purchased by Baxter, NYSE: BXT), Star Semiconductor (purchased by Logic Devices, Nasdaq: 

LOGC), and as a founding investor in IDEXX Laboratories (Nasdaq: IDXX) and TripAdvisor (purchased by InterActive 

Corp (Nasdaq: IACI). He is currently a Director of Flagship portfolio companies Abla-Tx, Acceleron Pharma, 

Aspect Medical (Nasdaq: ASPM), CERTUS Biomedical Inc, DataCore Software, EXACT Sciences (Nasdaq: EXAS), 

Interactive Supercomputing and Pervasis Therapeutics, and is Chairman of the Boards of TransMedics and VisEn 

Medical. Ed also serves as Chairman of the Board of Directors of Common Impact, a non-profit organization that 

provides information technology solutions for other non-profits and has been sponsored by Flagship Ventures. 

He is currently a director of the Massachusetts Biotechnology Council, a not-for-profit organization that provides 

services and support for the Massachusetts biotechnology industry, and a member of The Johhs Hopkins 

Medicine Alliance for Science and Technology Development Industry. 

9


Mark Leuchtenberger, Chairman, MBC Board of Directors 

Mark Leuchtenberger was President & Chief Executive Officer of Targanta Therapeutics Corporation until its acquisition by 

The Medicines Company in February. He joined Targanta in September 2006 and led the company’s successful series C round 

and IPO in 2007, raising more than $130 million. In 2008 Targanta filed for approval of its lead product oritavancin with both 

FDA and EMEA. Mr. Leuchtenberger came to Targanta from Therion Biologics Corporation, a privately held cancer vaccine 

company, where he served as President and Chief Executive Officer from 2002 to 2006. Under his leadership, Therion filed its 

first IND, progressed through Phase 3 trials, completed the buildup of its commercial manufacturing capabilities, and raised 

over $120 million in three rounds of private financings. 

Prior to joining Therion, Mr. Leuchtenberger was a senior officer at Biogen, where he served as Vice President, International 

from 1999-2002. In this capacity, he led all commercial operations outside of North America. He joined Biogen in 1990 and 

was responsible for managing the late-stage development, registration, marketing, and North American launch of Avonex®. 

He subsequently served as Vice President of Sales, Marketing and Business Development, where he oversaw North American 

commercial operations as well as Biogen’s global market, licensing and strategic partnership activities. Prior to Biogen, Mr. 

Leuchtenberger worked as a Senior Consultant at Bain and Company specializing in healthcare products and services. 

Mr. Leuchtenberger received an M.B.A. from the Yale School of Management and a B.A. from Wake Forest University. He is 

currently the Chairman of the Massachusetts Biotechnology Council Board of Directors and also serves on Boards for EPIX 

Pharmaceuticals, Beth Israel Deaconess Medical Center, and Wake Forest University. 

Eric Marcheski, Marchon Partners 

Mr. Marcheski co-founded Marchon Partners in 2008, bringing with him more than 13 years of human capital management 

experience. Prior to co-founding Marchon Partners, he held the role of Executive Director of Business Operations, at a 

$2 billion dollar provider of information technology and communication services firm. While there, he oversaw multiple 

acquisitions and mergers of the firm’s New England market. He is extremely passionate about the impact human capital 

has on the outcomes of organizations. Mr. Marcheski is a graduate of the University of Scranton. He is an Executive 

Committee member of the University of Scranton’s President’s Business Council and The Chief Executives Club of Boston. 

Mr. Marcheski currently resides outside Boston with his wife and three children. 

Lita Nelsen, Director of the MIT Technology Licensing Office 

Ms. Nelsen is the Director of the Technology Licensing Office at the Massachusetts Institute of Technology. This office 

manages over 500 new inventions per year from MITand Lincoln Laboratory. Typically, they negotiate over 100 licenses, 

and start up over 20 companies per year. 

Ms. Nelsen earned Bachelor of Science and Master of Science degrees in Chemical Engineering from MIT and a Master of 

Science in Management from MIT as a Sloan Fellow. 

Prior to joining the M.I.T. Technology Licensing Office, Ms. Nelsen spent 20 years in industry, primarily in the fields of 

membrane separations, medical devices, and biotechnology, at such companies as Amicon, Millipore, Arthur D. Little, Inc., 

and Applied Biotechnology. 

Ms. Nelsen was the 1992 President of the Association of University Technology Managers and serves on the Boards of 

the Biotechnology Industry Organization, the State of Massachusetts Technology Development Corporation and Mount 

Auburn Hospital, and has served on the Boards of the MIT Enterprise Forum, the Cornell Research Foundation and other 

boards. She has served as advisor to the NIH, the National Academy of Sciences and the Office of Technology Assessment. 

She is widely published in the field of technology transfer and university/industry collaborations. 

She was awarded the Bayh-Dole Award from the Associaton of University Technology Managers, shared the first Annual 

Award of the Massachusetts Society for Medical Research with Dean Flier of the Harvard Medical School, and was recently 

awardedd the honor of Memer of the Order of the British Empire (MBE) by the UK. 

10


The Hon. Deval L. Patrick, Governor, The Commonwealth of Massachusetts 

Governor Patrick was elected in November of 2006. He brings to the Governor’s office a broad range of leadership 

experience at the top levels of business, government, and non-profits. From an early age, he has built his life on hope, and 

traced a trajectory from the South Side of Chicago to the U.S. Justice Department, Fortune 500 boardrooms, and now the 

Massachusetts Statehouse. 

Mr. Patrick came to the Commonwealth at the age of 14. An excellent student despite the difficult circumstances of 

under-funded and often violent Chicago schools, he was awarded a scholarship to Milton Academy through A Better 

Chance, a Boston-based organization. 

After graduating from Milton, Mr. Patrick went on to Harvard, the first in his family to attend college. He received his 

degree, with honors, in 1978 and spent a post-graduate year working on a United Nations youth training project in the 

Darfur region of Sudan. He returned to Cambridge to attend Harvard Law School in the fall of 1979. 

Following law school, Mr. Patrick served as a law clerk to a federal appellate judge before joining the NAACP Legal Defense 

and Education Fund. In 1986, he joined the Boston law firm of Hill & Barlow and was named partner in 1990, at the age 

of 34. 

In 1994, President Clinton appointed Mr. Patrick Assistant Attorney General for Civil Rights, the nation’s top civil rights post. 

At the Justice Department, Mr. Patrick worked on a wide range of issues, including prosecution of hate crimes and abortion 

clinic violence, employment discrimination, and enforcement of fair lending laws and the Americans with Disabilities Act. 

During his tenure, Mr. Patrick led the largest criminal investigation prior to September 11th, coordinating state, local and 

federal agencies to investigate church burnings throughout the South in the mid-1990s. 

Mr. Patrick returned to private practice in 1997 with the Boston firm of Day, Berry & Howard. That same year, 

he was appointed by a federal district court to serve as the first chairperson of Texaco’s Equality and Fairness 

Task Force. Working with employees at all levels, Mr. Patrick and his Task Force examined and reformed Texaco’s 

complex corporate employment culture, and created a model for fostering an equitable workplace. Mr. Patrick was 

hired by Texaco in 1999 to serve as Vice President and General Counsel leading the company’s global legal affairs. 

In 2001, Mr. Patrick joined The Coca-Cola Company as Executive Vice President and General Counsel. He was elected to the 

additional role of Corporate Secretary in 2002, and served as part of the company’s senior leadership team as a member 

of the Executive Committee. 

Governor Mr. Patrick has served on numerous charitable and corporate boards, as well as the Federal Election Reform 

Commission under Presidents Carter and Ford, and as Vice Chair of the Massachusetts Judicial Nominating Council by 

appointment of Governor Weld. 

The Commonwealth’s first African-American Governor, Mr. Patrick came into office with a grassroots message of hope, 

community and hard work. By focusing on transparency and inclusion, he hopes to increase accessibility to government 

and encourage the civic engagement so crucial to shared progress in education, health care, economic development and 

other issues. 

Mr. Patrick and Diane have been married for over two decades and have two college-age daughters, Sarah and Katherine. 

The Patrick family has lived in Milton, in a house on Mr. Patrick’s high school paper route, for the last 17 years. 

11


Christopher Perley, Vice President and General Manager, Bristol-Myers Squibb 

Please see program insert 

Gerald E. Quirk, Vice President and General Counsel, Infinity Pharmaceuticals, Inc. 

Mr. Quirk is Vice President and General Counsel at Infinity Pharmaceuticals, Inc., a Cambridge-based oncology 

drug discovery and development company. Mr. Quirk has extensive experience representing biopharmaceutical 

companies in connection with licensing and other collaboration agreements, merger and acquisition transactions, 

clinical trials and product commercialization initiatives, and securities offerings and SEC compliance activities. Prior 

to joining Infinity in September 2006, Mr. Quirk served in a number of progressively responsible legal and business 

development positions at Genzyme Corporation. Mr. Quirk began his career as an associate in the business law 

department and biotechnology practice group at Palmer & Dodge LLP in Boston. Mr. Quirk earned his law degree 

from Northeastern University, a Master’s degree in Educational Administration from Harvard University, and a B.A. 

from Swarthmore College. 

Andrew Vaz, National Leader, Life Sciences, Deloitte Consulting LLP 

Mr. Vaz is the National Director of Deloitte’s Life Sciences practice responsible for all services and solutions. 

Mr. Vaz is also responsible for the development of all intellectual capital and methodologies to support the 

transformation of Life Sciences companies. He has over 20 years of experience in the healthcare industry across 

the Health Plan, Provider, Government Health, and Life Sciences sectors. Prior roles include Managing Director 

of the Canadian and Northeast Healthcare and Life Sciences practices at Ernst & Young. Mr. Vaz has also led the 

Healthcare Emerging Technology practice, as well as the Health High Growth practice for Cap Gemini Ernst & Young. 

Mr. Vaz’s consulting career has spanned strategy and business planning, business/technology enabled 

transformation, and the management of change. His client base has included large multi-national pharmaceutical, 

biotechnology and medical supply organizations, reference laboratories, large academic health sciences centers, 

academic organizations, integrated delivery systems, provider organizations across the continuum of care, 

managed care companies, and numerous health technology organizations. 

12

The MBC wishes to recognize and 

thank our event sponsors for their support 

Fisher Scientific 

Blue Cross Blue Shield of Massachusetts 

L.E.K. Consulting 

EMD Serono, Inc. 

Marchon Partners 

Bingham McCutchen LLP 

Cramer 

Goodwin Procter LLP 

Indigo Insurance Services, LLC 

KPMG LLP 

Nixon Peabody LLP 

Epicurean Feast 

13

Confidence in our today and tomorrow. 

Indigo Insurance Services is proud to support the 

Massachusetts Biotechnology Council. 

Indigo Insurance Services is a wholly owned subsidiary of Blue Cross Blue Shield of Massachusetts 

15

L.E.K. gets it. 

And we get it right. 

Succeeding in the life sciences demands strategic vision, sound 

data and superior execution. 

At L.E.K. Consulting, we get it. We understand the subtleties of 

the industry and the intricacies of the technology. We don’t just 

advise. We partner with our clients to help them address the 

big challenges and make the best decisions. 

And we get it right. Our commitment to fact– and data-driven 

analysis ensures we tell it like it is. No fluff. No spin. Solid 

strategic answers you can count on. 

www.lek.com 

Auckland • Bangkok • Beijing • Boston • Chicago • London • Los Angeles • Melbourne • Milan • Mumbai 

Munich • New Delhi • New York • Paris • San Francisco • Shanghai • Singapore • Sydney • Tokyo • Wroclaw 

16

Unmet needs. 

Unmet needs met. 

That’s our focus at EMD Serono. 

We’ve developed leading medicines for 

HIV-associated wasting, multiple sclerosis 

and fertility. We offer innovative drug 

delivery options for children with growth 

hormone deficiency. And we’re working 

on more than 30 new potential therapies 

for cancer, neurodegenerative diseases, 

autoimmune diseases, and other illnesses. 

We’re one of the world’s leading biopharmaceutical 

companies. And our values 

are reflected not only in our products, but 

in our programs of patient education and 

support, such as MS LifeLines®, Fertility 

LifeLines, SeroCare® and Connections 

for Growth®. 

The people of EMD Serono are focused on 

significant unmet medical needs. Meeting 

them. And helping people live more fully. 

Embracing life. Enhancing life. That is the 

spirit of EMD Serono. 

www.emdserono.com 

©2009 EMD Serono, Inc. 

17

Marchon Partners, a Boston based firm 

serving the Life Sciences community, 

is proud to sponsor the 

2009 MBC annual meeting. 

Transforming Human Capital Management 

31 State Street 

Boston, Ma 

617.720.4444 

www.marchonpartners.com 

18

Attorney Advertising © 2009 Bingham McCutchen LLP One Federal Street, Boston MA 02110 T. 617.951.8000 Prior results do not guarantee a similar outcome. 

GOOD NUMBERS 

The tougher the deal, the more we enjoy it. 

bingham.com 

400+ Life Sciences clients supported by 

160+ corporate, intellectual property, and 

litigation attorneys with 50+ advanced 

degrees in the life sciences sector 

900 Laywers | Boston | Hong Kong | London | Los Angeles | New York | San Diego 

San Francisco | Silicon Valley | Washington DC | www.goodwinprocter.com 

© 2009 KPMG LLP, the U.S. member firm of KPMG International, a Swiss cooperative. 11569HRT 

The most important ingredient 

for managing today’s healthcare 

challenges 

Insight. 

KPMG's Healthcare & Pharmaceuticals practice helps companies identify and 

manage business risks with a triple-strength formula for success: experience, 

industry focus, and insight. Our multidisciplinary teams of professionals 

deliver a wide range of services to help providers, payors, pharmaceutical 

and other life science companies manage risk and stay fiscally healthy— 

always keeping their strategic and financial goals in sight. 

For more information, please visit www.kpmghealthcarepharmainstitute.com 

us.kpmg.com 

The MBC would like to thank 

Fisher Scienc 

for their support of the 

2009 MBC Annual Meeng 

and is proud to have 

Fisher as the newest 

primary vendor in the 

MBC Purchasing Consorum. 

20

I don’t need theories from 

my lawyers. I need answers. 

Nixon Peabody congratulates 

Fereydoun Firouz, President and 

CEO of EMD Serono, Inc., 

recipient of the MBC Innovative 

Leadership Award, and 

a visionary leader of the 

biotechnology industry. 

Nixon Peabody Life Sciences practice, serving 

the full life cycle of biotechnology companies. 

nixonpeabody.com/lifesciences 

Nixon Peabody is proud to have EMD Serono, Inc. as a client. 

100 Summer Street ·Boston, MA · The person depicted in this ad is an actor depicting a fictional event. 

100 Summer Street ·Boston, MA · www.nixonpeabody.com/lifesciences 

21

Partners with 

For FREE Next-Day Delivery of all of your Office Supply needs 

at Amazingly Low Prices please call 

1-888-926-2766 

22

Clostridiumdifficile 

 

 

 

 

 

 

 

 

 

23

Risk is no place for the inexperienced. 

William Gallagher Associates Insurance Brokers, Inc. 

24

Imagine a world 

without creativity. 

We can’t either. 

Tufts Health Plan 

salutes you. 

25

Congratulations 

Fereydoun Firouz 

from your friends at 

A. W. PERRY, INC. 

EMD, Serono, Inc. 

One Technology Place, Rockland, MA 

Serving the South Shore as Owners and Developers of 

South Shore Park and South Shore Technology Park 

Real Estate Investment, Development & Management 

Twenty Winthrop Square, Boston ✥ Four Pond Park Rd., Hingham 

Te l e p h o n e 6 1 7 . 5 4 2 . 3 1 6 4 ✥ w w w. AW P e r r y. c o m 

26

WeissComm Partners joins the Massachusetts Biotechnology Council 

in congratulating Fereydoun Firouz, President & CEO, EMD Serono, Inc., 

on his receipt of the 

MBC Innovative Leadership Award. 

We commend Mr. Firouz for his dedication to the biotechnology 

industry, commitment to patient care, and his leadership both 

locally and globally. 

Because Results Matter 

©2009 WeissComm Partners. All rights reserved. 

27

Congratulations, Fereydoun! 

Your spirit of innovation has propelled EMD 

Serono, Inc. as a world-class organization focused 

on meeting patients’ unmet needs. With a strong 

commitment to educational support services and 

call centers, employee excellence and community, 

you have built a one of a kind organization. 

We are proud to be a marketing partner of 


- Your friends at Cramer 

28

MBC Committee Chairs 

Thank you to the MBC Committee Chairs 

Massachusetts Biotechnology Council members have an opportunity to come on a regular basis to 

network and learn more about their complex, ever-changing field through our Member Committee 

Meetings. These meetings allow our members to discuss and share their ideas, advice and experiences 

with the numerous challenges and opportunities that life science companies face every day. 

Each committee is chaired by volunteers from member organizations who help arrange educational 

seminars featuring keynote speakers and panels to address a wide variety of current topics. 

The MBC wishes to recognize and thank each of our committee chairs for their hard work and dedication 

to delivering valuable content to their fellow members. 

Business Development 

Brian Fenton, Idenix, Inc. 

Clare Fisher, Genzyme Corporation 

Ashley Stevens, Boston University, 

Office of Technology Transfer 

Christopher de Souza, SkyePharma 

Biostatistics/Data Management 

Jon Haddad, Synta Pharmaceuticals Corporation 

Cindy Steinberg, BioBridges LLC 

Clinical Trials 

LeeAnn I . Ali, Sepracor Inc. 

Larry Blankstein, Genzyme Corporation 

Michelle Lim-Watson, Abt Bio-Pharma Solutions, Inc. 

Kathy Ford, Millennium Pharmaceuticals, Inc. 

Entrepreneur University 

John Hallinan, Cytel, Inc. 

John Hession, Cooley Godward Kronish 

Marc Recht, Cooley Godward Kronish 

Formulation and Drug Delivery 

Michiel Lodder, OctoPlus, Inc. 

Law and Policy 

Maria Buckley, Nutter, McClennen & Fish, LLP 

Patrick Waller, Wolf, Greenfield, & Sacks, P.C. 

Tad Heuer, Foley Hoag 

Drug Discovery 

Neal Birnberg, Mercury Therapeutics 

Nils Bergenhem, Escoublac, Inc. 

Robert Bondaryk, Symbiosis Scientific 

Finance 

John Hallinan, Cytel Inc. 

Christopher Kennedy, Sturgeon Investments 

Human Resources 

Pat Abbott, Venture Forward Partners 

Carolyn Fuchs, Crf Associates 

Life Science Informatics 

Grant Stephen, Tessella Inc. 

30

MBC Committee Chairs 

Marketing/Communications 

Lynne Brum, Porter Novelli Life Sciences 

Catherine Cloft, LaVoie Strategic Communications Group 

Ellen Flipse, Dyax Corporation 

Donna LaVoie, LaVoie Strategic Communications Group 

Process Development 

Thomas Harrington, Lonza Hopkinton, Inc. 

Gerry Nicklas, Acambis, Inc. 

Robert Shaw, Millipore Corporation 

Project Management 

Lydia Harris, Project Office Services 

James Weston, Alseres Pharmaceuticals 

Susan Macdonald 

Quality/Regulatory 

Linda Lemieux, Advanced Cell Technology 

Pam Gustafson, Proteon Therapeutics 

Safety, Environmental and Facility Operations 

Deborah Benjamin, Dyax Corporation 

Susan Smits, Mabbett & Associates, Inc. 

Security 

David Kent, Genzyme Corporation 

Technology 

Jeffrey Blander, Harvard Medical School/MIT and Bienmoyo 

31

MBC Board of Directors 

Chair 

Vice-Chair 

Treasurer 

Clerk 

Immediate Past Chair 

Mark Leuchtenberger, Former CEO Targanta Therapeutics 

Geoffrey F. Cox, GTC Biotherapeutics, Inc. 

Michael W. O’Hara, Deloitte 

Glenn Batchelder, BIND BioSciences, Inc. 

Mike D. Webb, Exponential Pharma Ventures 

MBC Board Members 

Mark R. Bamforth 

Genzyme Corporation 

Erroll De Souza 

Archemix Board of Directors 

Jeffrey J. Elton 

Biotechnology Consultant and Private Investor 

Edwin M. Kania, Jr. 

Flagship Ventures 

Dr. Michael Kowolenko 

Wyeth Biotech Technical Operations and Product Supply 

Laurie Bartlett Keating 

Millenium Pharmaceuticals 

W. Stephen Faraci David Reif 

Pfizer, Inc. 

MBEF Representative 

Fereydoun Firouz 


Scott Gillis 

Former CEO, NUCRYST Pharmaceuticals 

John K. Hennessy 

AstraZeneca Pharmaceuticals, LLP 

Timothy Hunt 

Biogen Idec 

Counsel 

Steven G. Richter 

MicroTest Laboratories, Inc. 

Amit Sachdev 

Vertex Pharmaceuticals, Inc. 

Frank Thomas 

Molecular Biometrics 

Lawrence S. Wittenberg 

Goodwin Procter LLP 

Legislative 

Communication 

William P. McDermott 

McDermott, Quilty & Miller LLP 

Robert Gottlieb 

32

MBC Staff 

Robert K. Coughlin 

President and CEO 

Imran Nasrullah 

Chief Business Officer 

John Heffernan 

Vice President, Policy & External Affairs 

Peter Abair 

Director, Economic Development 

Kara Boniface 

Executive Assistant to the President and Office Manager 

Kendalle Burlin Brown, Esquire 

Director of Purchasing & Contracts 

Joseph Fazio 

Director, Finance 

Kendra Howard 

Manager, Human Resources 

Michael Grant 

Manager, Business Development 

Kathryn Kilroy 

Manager, Member Services 

Lauren Laidlaw 

Director, Member Services 

Sarah MacDonald 

Director, Communications 

Melinda Moy 

Operations Assistant 

Stephen Mulloney 

Director, Policy & Public Affairs 

Jeff Ouimette 

Manager, Information Technology 

Adam Pittman 

Manager of Database Development & Programming 

Halley Smith 

Administrative Assistant 

MBEF Staff 

Lance Hartford 

Executive Director 

Lisa O’Connell 

Program Administrative Assistant 

Robert Ross 

Director, BioTeach Program 

Hannah Yun 

Manager, Education & Training Programs 

Suzanne Grillo 

Manager, Website Marketing 

33

About the MBC 

The Massachusetts Biotechnology Council (MBC), a not-for-profit organization that represents and provides 

services and support for the Massachusetts biotechnology industry, is the nation’s oldest biotechnology 

trade association. Founded in 1985, the MBC is committed to advancing the development of critical new 

science, technology and medicines that benefit people worldwide. Representing over 600 biotechnology 

companies, academic institutions, research hospitals, and service organizations involved in life sciences and 

health care, the MBC works to advance policy and promote education, while providing member programs 

and events, industry information, and services. 

Public Policy and Industry Development 

Working in consultation with the MBC Board, member companies, government agencies and administration 

at the state and federal level, the MBC develops and implements legislative and regulatory strategies 

designed to promote biotechnology’s successful growth. The MBC is fully engaged in the public arena and 

active in policy and politics from town boards and committees, right through to Capitol Hill. The MBC also 

promotes economic development by identifying and accessing opportunities for biotechnology research, 

development, and manufacturing. The MBC encourages continued support and expansion of the industry in the 

Commonwealth, providing guidance and resources on location, permitting, technical, and funding requirements. 

Purchasing Power 

One of the most powerful benefits of the MBC’s long history and position in the industry is access to savings 

through the Purchasing Consortium. The consortium negotiates a broad-based collection of contracts and 

services on behalf of member companies, and provides substantial cost savings for large and small companies. 

These discounts help a company’s bottom line by saving money on both supplies and services. 

Professional Development and Educational Forums 

Recognizing that motivated and talented individuals are the driving force behind science, the MBC manages 

17 active committees open only to employees of member organizations. Specializing in topics ranging from 

Drug Discovery and Life Science Informatics to Human Resources and Business Development, these groups 

hold regular professional development forums and provide consistent education to industry professionals. 

Educational Initiatives 

The MBC is committed to increasing science education and the science, technology, engineering and math 

(STEM) pipeline across Massachusetts. The organization, in conjunction with the MassBioEd Foundation, 

has committed to finding solutions to identified industry needs for a robust workforce in the future. 

MBC Signature Events 

The MBC organizes major annual events in pursuit of our goal to attract innovation and support industry 

advancement in the Commonwealth. Members and others in the industry enjoy our Policy Luncheon, 

Annual Meeting, MassBio Investors Forum, MassBioEd/MBC Golf Classic and other special events 

throughout the year. 

34

School Programs • Workforce Training • Lifelong Learning 

Committed to the Development and Education 

of the Present and Future Biotechnology 

Workforce in Massachusetts 

BLC MISSION: 

To enable the Massachusetts biotechnology workforce to become leaders 

in the biotech industry. MassBioEd offers courses, seminars and indepth 

training for biotechnology professionals and the adult public. 

All of our Programs are: 

Designed and taught by biotechnology industry experts. 

Offered for credit towards professional or continuing education units. 

Current Course Offerings Include: 

Biotechnology Project Management 

An Overview of Clinical Research 

Customized Courses Available: 

MassBioEd also customizes training programs for companies and 

educational institutions. Examples of recently customized courses are: 

Leadership on the Plant Floor 

Physicians in Clinical Research 

BioTeach brings the excitement of scientific discovery to biology classrooms 

across the state, inspiring students of all abilities to pursue diverse careers in the 

life sciences. 

BIOTEACH MISSION: 

To enable every public high school in Massachusetts to teach biotechnology. 

BioTeach leverages existing educational programs, builds corporate and 

educational partnerships, and provides schools with: 

Up to $9,000 in new science lab equipment 

Workshops on biotechnology for teachers 

Engaging wet labs for students, including activities about the wide range 

of exciting careers in biotech 

Sustainability plans for replenishing supplies and biennial supplemental training 

FOR MORE INFORMATION, PLEASE CONTACT MBEF-REQUEST@MASSBIO.ORG 

OR VISIT US AT WWW.MASSBIOED.ORG.

Massachusetts Biotechnology Council 

One Cambridge Center 

Cambridge, MA 02142 

P 617.674.5100 

F 617.674.5101 

www.massbio.org

The MBC wishes to recognize and 

thank our event sponsors for their support 

PhRMA 

Jack Morton Worldwide 

A

True innovators show us 

not just what’s possible, 

but prove that nothing 

is impossible. 

We congratulate Fereydoun Firouz on winning the Innovative Leadership Award. 

We are proud sponsors of Mass Bio and its community of innovators. 

B

The Pharmaceutical Research 

and Manufacturers of America 

applauds 

Fereydoun Firouz, CEO, EMD Serono 

as he accepts the 

MBC Innovat Leadership Award 

We are grateful for our strong partnership 

with the Massachusetts Biotechnology Council 

and for their commitment to research and 

efforts to make Massachusetts a world 

center for biopharmaceutical innovation. 

New Medicines. New Hope. 

www.phrma.org | www.pparx.org | www.fightchronicdisease.org 

C


Christopher Perley, Vice President and General Manager, Bristol-Myers Squibb 

Christopher Perley joined Bristol-Myers Squibb in 2008. He leads the BMS Large Scale Cell 

Culture organization in the global supply of protein therapeutics. He has 30 years of experience 

in manufacturing and process development in the pharmaceutical and biotechnology industries. 

Mr. Perley earned a Master’s degree in Biochemical Engineering from the MIT and an MBA from 

Boston University. 

Neal C. Comstock, Executive Vice President for Administration and 

Secretary, Pharmaceutical Research and Manufacturers of America 

Neal Comstock joined PhRMA in January 2002 as Senior Advisor and Executive Secretary. 

Now as Executive Vice President and Corporation Secretary, he assists the President and CEO, 

Billy Tauzin, in managing PhRMA on a daily basis. Specifically, he has responsibility for Board-level 

meetings, meeting planning, Human Resources and membership relations. 

Previously, Mr. Comstock served as Executive Secretary of the U.S. Department of the Treasury 

under Secretaries Robert Rubin and Lawrence Summers. He also served as Deputy Executive 

Secretary under Treasury Secretary Lloyd Bentsen. His experience also includes working on Capitol 

Hill, on political campaigns and in private law practice. 

Mr. Comstock is an attorney admitted to the Connecticut Bar who graduated from the University 

of Connecticut School of Law in 1991 and the Catholic University of America in Washington, D.C in 

1988. He is married to Stephanie Corrao, and they have three sons. 

D

Speaker Bios - Massachusetts Biotechnology Council

Create successful ePaper yourself

Delete template?

Save as template?